Literature DB >> 8005662

Bactericidal activity of synthetic peptides based on the structure of the 55-kilodalton bactericidal protein from human neutrophils.

B H Gray1, J R Haseman.   

Abstract

Short (10- to 11-mer) hydrophilic peptides based on the structure of the 55-kDa bactericidal protein (BP55, B/PI, and CAP57) from human neutrophil granules were identified from the hydropathy plot of the 456-amino-acid sequence predicted from the nucleotide sequences of cDNA clones for BP55 and B/PI. Peptides corresponding to amino acid residues 90 to 99 (peptide #90-99), 86 to 99, or 90 to 102 of BP55 were bactericidal toward 5 x 10(6) Pseudomonas aeruginosa cells at 0.6 x 10(-5) to 1.5 x 10(-5) M and killed an Escherichia coli rough strain at 3 x 10(-5) M. The #90-99 peptide with a cysteine added at the amino terminus (C#90-99) was approximately 10 times more active than #90-99, killing P. aeruginosa at 1.5 x 10(-6) M. Peptides representing amino acid residues 27 to 37, 118 to 127, and 160 to 170 and the first 10 amino acids of the signal sequence for BP55 were not bactericidal. When coupled to either keyhole limpet hemocyanin or ovalbumin protein carriers through the thiol group, the C#90-99 peptide was not diminished on a molar basis in its capacity for killing of P. aeruginosa. Two other relatively hydrophilic peptides with an added amino-terminal cysteine, peptides C#227-236 and C#418-427, were not bactericidal at 1.2 x 10(-4) M or at 100 times the effective bactericidal concentration of C#90-99. The C#90-99 peptide killed E. coli at 1.5 x 10(-5) M, or at 10 times the concentration required to kill an equal number of P. aeruginosa cells. Although Pseudomonas cepacia and Staphylococcus aureus were resistent to killing by the parent BP55 molecule, they were susceptible to the C#90-99 and #90-99 peptides in the same concentration range as was E. coli. When all peptides were compared for the ability to neutralize E. coli O55:B5 endotoxin in a Limulus amoebocyte lysate assay, the C#227-236, C#418-427, and #160-170 peptides completely inhibited gelation at a 10(-4) M concentration. All other synthetic peptides, including bactericidal peptide #90-99 and its congeners, lacked endotoxin-neutralizing activity at the highest concentration tested (4.5 x 10(-4) M). A hybrid of the C#227-236 and #90-99 peptides (CHybrid) was identical to the C#227-236 peptide component in effectiveness for carrying out endotoxin neutralization and was fivefold better than the #90-99 peptide in its capacity for killing P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005662      PMCID: PMC302875          DOI: 10.1128/iai.62.7.2732-2739.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Characterization of a protein from normal human polymorphonuclear leukocytes with bactericidal activity against Pseudomonas aeruginosa.

Authors:  C J Hovde; B H Gray
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  Physiological effects of a bactericidal protein from human polymorphonuclear leukocytes on Pseudomonas aeruginosa.

Authors:  C J Hovde; B H Gray
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

4.  Cationic antimicrobial proteins isolated from human neutrophil granulocytes in the presence of diisopropyl fluorophosphate.

Authors:  W M Shafer; L E Martin; J K Spitznagel
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

5.  Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity.

Authors:  M N Marra; C G Wilde; J E Griffith; J L Snable; R W Scott
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

6.  Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations.

Authors:  P W Gray; G Flaggs; S R Leong; R J Gumina; J Weiss; C E Ooi; P Elsbach
Journal:  J Biol Chem       Date:  1989-06-05       Impact factor: 5.157

7.  A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis.

Authors:  P S Tobias; J C Mathison; R J Ulevitch
Journal:  J Biol Chem       Date:  1988-09-25       Impact factor: 5.157

8.  Environmental modulation of lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the neutrophil bactericidal/permeability-increasing protein.

Authors:  J Weiss; M Hutzler; L Kao
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

9.  Lipopolysaccharide structure determines ionic and hydrophobic binding of a cationic antimicrobial neutrophil granule protein.

Authors:  M M Farley; W M Shafer; J K Spitznagel
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

10.  A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein.

Authors:  C E Ooi; J Weiss; P Elsbach; B Frangione; B Mannion
Journal:  J Biol Chem       Date:  1987-11-05       Impact factor: 5.157

View more
  3 in total

1.  Enterohemorrhagic Escherichia coli O157:H7 gal mutants are sensitive to bacteriophage P1 and defective in intestinal colonization.

Authors:  Theresa Deland Ho; Matthew K Waldor
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

2.  Evidence of a bactericidal permeability increasing protein in an invertebrate, the Crassostrea gigas Cg-BPI.

Authors:  Marcelo Gonzalez; Yannick Gueguen; Delphine Destoumieux-Garzón; Bernard Romestand; Julie Fievet; Martine Pugnière; Françoise Roquet; Jean-Michel Escoubas; Franck Vandenbulcke; Ofer Levy; Laure Sauné; Philippe Bulet; Evelyne Bachère
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-26       Impact factor: 11.205

3.  The Vibrio cholerae ToxR-regulated porin OmpU confers resistance to antimicrobial peptides.

Authors:  Jyoti Mathur; Matthew K Waldor
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.